Amaero (3DA) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
21 Aug, 2025Business overview and market positioning
Leading U.S. producer of high-value refractory and titanium alloy spherical powders, manufacturing near-net-shape parts for mission-critical components in defense, space, aviation, medical, and industrial sectors.
Largest and lowest-cost U.S. domestic producer in its segment, leveraging advanced EIGA Premium technology and a Tennessee-based facility.
Strong balance sheet with A$19.2 million in cash as of June 30, 2025, and A$70 million in tangible assets and cash.
Positioned to benefit from U.S. reshoring trends and supply chain resilience initiatives.
Strategic partnerships and commercial traction
Secured five-year preferred supplier agreement with ADDMAN Group for C103 and titanium alloy AM powder, following successful qualification.
Exclusive five-year supplier agreement with Velo3D, expected to generate ~A$35M in revenue from C103 and titanium alloy powder sales.
Received contracts from a U.S. Department of Defense Prime Contractor and commenced collaboration with Boeing.
Orders from 14 customers for Q1 FY26, including major defense and aerospace players.
Financial performance and growth outlook
Entered FY26 with contracted revenue covering ~80% of planned 1H revenue.
Q1 FY26 revenue estimated at ~A$5.5M, a 550% increase from Q1 FY25 and 145% above all of FY25.
Expects to significantly scale revenue in FY26 and achieve positive EBITDA in FY27.
Fully funded through to free cash flow for existing capex plan; additional funding to accelerate growth initiatives.
Latest events from Amaero
- FY2025 saw record revenue, major supply deals, and facility expansion, setting up strong FY2026 growth.3DA
H2 202531 Mar 2026 - Strategic U.S. shift, capital raises, and C103 supply deals set path to EBITDA breakeven by FY2026.3DA
H2 202431 Mar 2026 - Revenue up 367%, net loss widens, FY2026 guidance cut amid U.S. contract delays.3DA
H1 202612 Feb 2026 - Transition to commercialization, capital raises, and U.S. expansion with new leadership.3DA
AGM 202418 Jan 2026 - Seven resolutions, including share placements and a name change, were presented and voted online.3DA
EGM 202524 Dec 2025 - Production and revenue scale rapidly with new atomizer, strong contracts, and U.S. market demand.3DA
Status Update12 Nov 2025 - Revenue up 445% YoY to AUD 4.7M; AUD 50M raised; FY2026 guidance AUD 30–35M.3DA
Q1 2026 TU24 Oct 2025 - Revenue, production, and strategic partnerships surged, driving rapid commercial expansion.3DA
Investor Presentation23 Oct 2025 - Exclusive Titomic deal, capacity expansion, and strong FY26 growth pipeline drive momentum.3DA
Investor Update16 Sep 2025